Anebulo Pharmaceuticals Announces Appointment of Nat Calloway, Ph.D., to Board of Directors
November 01 2022 - 3:00PM
Business Wire
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a
clinical-stage biopharmaceutical company developing novel solutions
for people suffering from acute cannabinoid intoxication (ACI) and
substance abuse disorder (the “Company” or “Anebulo”), today
announced the appointment of Dr. Nat Calloway to its Board of
Directors. Dr. Calloway will serve as a member of the Compensation
Committee of the Board.
“We are very pleased to welcome Nat to the Anebulo Board,” said
Simon Allen, Chief Executive Officer of Anebulo. “Nat’s deep
experience within the investment community and strong healthcare
background will be invaluable to Anebulo as we continue the
development of ANEB-001.”
Dr. Calloway is an analyst and partner at 22NW, LP, a
Seattle-based value fund specializing in small and microcap
investments with a multi-year investment horizon, where he has been
employed since June 2021. Dr. Calloway is the lead for 22NW, LP’s
biotechnology, pharmaceutical and other healthcare investments,
including Anebulo Pharmaceuticals, Inc. Prior to that, Dr. Calloway
was the Associate Director of Healthcare Research for Edison Group
from December 2015 to June 2021. He has a PhD in Chemistry and
Chemical Biology from Cornell University, a Masters of Science in
Chemistry from Columbia and completed a post-doctoral study in
neuroscience at Weill Cornell Medical School. He has 10 scientific
publications in the areas of physical chemistry, biochemistry and
neuroscience.
About Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company developing novel solutions for people
suffering from acute cannabinoid intoxication and substance abuse
disorder. Its lead product candidate, ANEB-001, is currently in a
Phase 2 clinical trial
(www.clinicaltrials.gov/ct2/show/NCT05282797) to evaluate its
utility in reversing the negative effects of acute cannabinoid
intoxication within one hour of administration. This trial is being
run in the Netherlands by the Centre for Human Drug Research
(CHDR). ANEB-001 is a competitive antagonist at the human
cannabinoid receptor type 1 (CB1). For further information about
Anebulo, please visit www.anebulo.com.
Forward-Looking Statements
This press release contains forward-looking statements as
defined in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
These forward-looking statements, along with terms such as
“anticipate,” “expect,” “intend,” “may,” “will,” “should” and other
comparable terms, involve risks and uncertainties because they
relate to events and depend on circumstances that will occur in the
future. Those statements include statements regarding the intent,
belief or current expectations of Anebulo Pharmaceuticals and
members of its management, as well as the assumptions on which such
statements are based. Prospective investors are cautioned that any
such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, including risks
attendant to developing, testing and commercializing the company’s
product candidates, and those described in Anebulo Pharmaceutical’s
most recent annual report on Form 10-K and in other periodic
reports filed with the SEC, and that actual results may differ
materially from those contemplated by such forward-looking
statements. Except as required by federal securities law, Anebulo
Pharmaceuticals undertakes no obligation to update or revise
forward-looking statements to reflect changed conditions.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221101006250/en/
Anebulo Pharmaceuticals, Inc. Scott Anderson Head of
Investor Relations and Public Relations (858) 229-7063
scott@anebulo.com
Rex Merchant Chief Financial Officer (512) 598-0931
IR@anebulo.com
Anebulo Pharmaceuticals (NASDAQ:ANEB)
Historical Stock Chart
From Apr 2024 to May 2024
Anebulo Pharmaceuticals (NASDAQ:ANEB)
Historical Stock Chart
From May 2023 to May 2024